Welcome to Peptide Card of AntiTbPdb
| This page displays user query in tabular form. |
STLHLVLRLRGG details |
| Primary information | |
|---|---|
| ID | antitb_1302, |
| Name | 19682257 |
| N-Terminal modification | Ubiquitin-derived peptide (Ub2) |
| C-Terminal Modification | STLHLVLRLRGG |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 12 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Ubiquitin derived |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | M. smegmatis mc2 155 |
| Cell Line | 1.5 fold reduction in bacterial colony as compared to control at 50 μM of peptide |
| Inhibition Concentration | In vitro |
| Sequence | 2009 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Pore formation in Mycobacterial membrane |
| Other activities | mspA gene which form porins in membrane, peptide increase the expression of this gene |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1303, |
| Name | 19682257 |
| N-Terminal modification | Ubiquitin-derived peptide (Ub2) |
| C-Terminal Modification | STLHLVLRLRGG |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 12 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Ubiquitin derived |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | M. smegmatis mc2 155 |
| Cell Line | 1.5 fold reduction in bacterial colony as compared to control at 60 μM of peptide |
| Inhibition Concentration | In vitro |
| Sequence | 2009 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Pore formation in Mycobacterial membrane |
| Other activities | mspA gene which form porins in membrane, peptide increase the expression of this gene |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1304, |
| Name | 19682257 |
| N-Terminal modification | Ubiquitin-derived peptide (Ub2) |
| C-Terminal Modification | STLHLVLRLRGG |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 12 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Ubiquitin derived |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | M. smegmatis mc2 155 |
| Cell Line | 2.5 fold reduction in bacterial colony as compared to control at75 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2009 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Pore formation in Mycobacterial membrane |
| Other activities | mspA gene which form porins in membrane, peptide increase the expression of this gene |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1305, |
| Name | 19682257 |
| N-Terminal modification | Ubiquitin-derived peptide (Ub2) |
| C-Terminal Modification | STLHLVLRLRGG |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 12 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Ubiquitin derived |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | M. smegmatis mc2 155 |
| Cell Line | 3 fold reduction in bacterial colony as compared to control at100 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2009 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Pore formation in Mycobacterial membrane |
| Other activities | mspA gene which form porins in membrane, peptide increase the expression of this gene |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1540, |
| Name | 25613372 |
| N-Terminal modification | Ub2 |
| C-Terminal Modification | STLHLVLRLRGG |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 12 |
| Source | L |
| Origin | Cationic |
| Species | Protein derived |
| Strain | Derived from human ubiquitin protein |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = 5 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Disrupt the mycobacterial membrane |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Bactericidal against pseudomonas and staphylococcus at pH 5.5 |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1816, |
| Name | 23173767 |
| N-Terminal modification | ubiquitin-derived peptide Ub2 |
| C-Terminal Modification | STLHLVLRLRGG |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 12 |
| Source | L |
| Origin | Cationic |
| Species | Protein Derived |
| Strain | Ubiquitin derived |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis mc2155 |
| Cell Line | MIC = 50 μM |
| Inhibition Concentration | In vitro |
| Sequence | 2012 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Micellar aggregate channel model |
| Other activities | Cytoplasmic membrane |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |